Abstract
Icatibant, an antagonist of the bradykinin B2 receptor, was approved for the treatment of acute attacks of hereditary angioedema in the EU in 2008. This paper presents the case of a 65-year-old woman affected by frequent acute attacks of hereditary angioedema who benefitted from a change of therapy to icatibant, following years of treatment with C1-inhibitor.
Publication types
-
Case Reports
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Angioedemas, Hereditary / drug therapy*
-
Bradykinin / analogs & derivatives*
-
Bradykinin / therapeutic use
-
Bradykinin B2 Receptor Antagonists*
-
Complement C1 Inhibitor Protein / analysis
-
Complement C1 Inhibitor Protein / therapeutic use
-
Female
-
Humans
Substances
-
Bradykinin B2 Receptor Antagonists
-
Complement C1 Inhibitor Protein
-
icatibant
-
Bradykinin